Here, we discovered that the delivery of Stk25-targeting ASOs, which commenced at the advanced stage of MASH when first HCC tumors had already developed in most mice, resulted in similar efficacy to ASO administration initiated at the early phase of MASLD. The gene discussed is STK25; the disease is metabolic dysfunction-associated steatohepatitis.